A chemist works in BeiGene’s labs in Beijing.
Credit: Beigene
A chemist works in BeiGene’s labs in Beijing.
Credit: Beigene
Germany's Merck Gets Chinese Cancer Drug
Pharmaceutical R&D: Deal signals growing Western confidence in Chinese inventions.
Merck Serono will pay up to $233 million to the Beijing-based drug discovery firm BeiGene for marketing rights outside China to a cancer drug candidate. BeiGene says its compound may be effective against melanoma, colorectal cancer, and other forms of the disease. Human trials of the drug are expected to begin next year.
The deal marks the second time in less than two years that a multinational company has acquired rights to a drug invented in China. In December 2011, Shanghai-based Hutchison MediPharma agreed to license to AstraZeneca the global rights to volitinib, a tyrosine kinase inhibitor being developed as a cancer treatment.
No comments:
Post a Comment